What is the primary problem Pure Medical is addressing?

According to slide 2, Pure Medical is addressing the 31 million adults in the UK living with chronic pain. They aim to provide proactive wellness services that offer convenient, efficient, and intuitive experiences for injury recovery, athletic performance, and longevity, moving beyond the limitations of conventional healthcare disruption.

How does Pure Medical plan to integrate with the public health system?

Slide 2 notes that the company has secured a Letter of Intent (LOI) with the Milton Keynes NHS trust. This contract, intended to start in July 2022, provides a population catchment of 6.1 million public sector patients. They are also in ongoing negotiations with neighboring NHS trusts to expand this reach.

What specific medical treatments does the company offer?

Slide 6 lists ten distinct modalities: Hyperbaric oxygen therapy, Photobiomodulation therapy, Tailored medical plans, Cryotherapy, Far infrared sauna therapy, Ozone therapy, Cryolipolysis therapy, IV drip therapy, Physio+ therapy, and Compression therapy. Slides 4 and 5 provide deep dives into the science behind infrared sauna and ozone therapies.

What is the 'Care Pyramid' mentioned in the deck?

Slide 7 describes the Care Pyramid as a method to align resources with patient requirements. It scales from 'Digital Self-care' at the base (app-based monitoring) up through 'Personal Health Assistants' and 'Virtual Clinical Consultations' to 'In Person Consultation' and 'Tailored Healthcare' at the peak.

What are the terms of the current funding round?

As shown on slide 10, Pure Medical is raising approximately £2.5M. This is structured as a placement of 99,404 New B Shares priced at £25.15 per share. The funds are earmarked for the acquisition of medical machinery, development of clinical sites, and additional headcount.

Pure Medical Pitch Deck Teardown: A Hybrid Clinical

Pure Medical's investor deck outlines a strategy to become a UK leader in Proactive Wellness Services (PWS), addressing chronic pain and longevity. The company leverages a hybrid model that includes physical clinical treatments—such as infrared sauna and intravenous ozone therapy—alongside a digital 'Care Pyramid' featuring virtual consultations and self-care apps. A key validator cited is a Letter of Intent (LOI) with the Milton Keynes NHS trust, potentially reaching 6.1 million patients. Financially, the company targets 60%+ margins in clinical services and is seeking £2.5M via a placement…

Key takeaways

The company identifies a market of 31 million adults in the UK living with chronic pain as its primary target audience (Slide 2).
Pure Medical claims a 'Blue Ocean' status, stating no other UK facility offers their specific spectrum of 10 treatment modalities (Slide 6).
A central traction point is a secured LOI for a Patient Clinical Pathway Contract with Milton Keynes NHS trust, scheduled for July 2022 (Slide 2).
The business model targets high-profitability clinical services with projected margins exceeding 60% (Slide 2).
The 'Care Pyramid' strategy aims to move patients from high-cost tailored healthcare down to lower-cost digital self-care and monitoring (Slide 7).
The company is seeking to raise approximately £2.5M through the issuance of 99,404 New B Shares at a price of £25.15 per share (Slide 10).
Treatment offerings are diverse, including specialized therapies like Intravenous Ozone Therapy and Hyperbaric Oxygen Therapy (Slide 5, Slide 6).
Operational leverage is expected to come from automating administrative tasks and using digital triage to utilize lower-cost healthcare professionals (Slide 9).

Executive Summary and Brand Identity

Slide 1: Title Slide

The deck opens with the Pure Medical logo, featuring the brand name and the sub-brand 'Pure Restore Health.' The imagery includes a stylized medical cross integrated with a leaf/humanoid figure, suggesting a blend of clinical medicine and natural wellness. The slide is dated December 2021.

Slide 2: Understanding Pure Medical in 5 Questions

This slide serves as a high-level executive summary. It identifies the problem as 31 million UK adults living with chronic pain. The solution is defined as 'Proactive Wellness Services' (PWS). Key accomplishments include a secured LOI with the Milton Keynes NHS trust, covering 6.1 million patients, starting July 2022. The monetization strategy claims 60%+ margins in clinical services, and growth is planned through replicating the model with new customers and selective acquisitions.

Clinical Modalities and Technology

Slide 3: Transition - How Do We Do It?

A transition slide featuring a high-contrast image of a woman standing in front of a red light therapy panel, reinforcing the high-tech wellness aesthetic.

Slide 4: Infrared Sauna Therapy

This slide provides a technical breakdown of infrared sauna therapy. It distinguishes between near, mid, and far-infrared wavelengths, claiming benefits ranging from deeper tissue penetration to detoxification. A prominent callout at the bottom states 'OVER 30 CONDITIONS TREATED WITH INFRARED SAUNA,' and a sidebar lists conditions such as diabetes, high blood pressure, and Alzheimer's disease.

Slide 5: Intravenous Ozone Therapy

Pure Medical positions itself as one of only a handful of UK clinics offering Intravenous Ozone Therapy (Major Autohemotherapy). The slide cites a 2018 research study regarding knee osteoarthritis and mentions clinical trials for heart disease and arthritis. Similar to the previous slide, it claims 'OVER 30 CONDITIONS TREATED WITH INTRAVENOUS THERAPY' and lists cancer, macular degeneration, and immune disorders in the sidebar.

Slide 6: Pure Medical Blue Ocean Opportunity

This slide visualizes the 'Blue Ocean' strategy by displaying ten distinct treatment modalities in an octagonal grid. The treatments listed are: 1) Hyperbaric oxygen therapy, 2) Photobiomodulation therapy, 3) Tailored medical plan, 4) Cryotherapy, 5) Far infrared sauna therapy, 6) Ozone therapy, 7) Cryolipolysis therapy, 8) IV drip therapy, 9) Physio+ therapy, and 10) Compression therapy. The header explicitly states that no other UK facility offers this specific spectrum.

Operational Strategy and Scalability

Slide 7: The Care Pyramid

This slide outlines the patient journey and resource allocation. The pyramid structure starts with 'Digital Self-care' (app and monitoring) at the base, moving up to 'Personal Health Assistant' (non-clinical support), 'Virtual Clinical Consultation,' 'In Person Consultation,' and finally 'Tailored Healthcare' at the top. This suggests a funnel designed to manage costs by using digital tools for lower-intensity needs.

Slide 8: Transition - How Do We Monetize It?

A transition slide showing a medical professional administering an IV, emphasizing the clinical nature of the revenue-generating services.

Slide 9: Margin Expansion and Operational Leverage

Pure Medical explains how they intend to expand margins. The strategy is two-fold: providing wellness-first end-to-end care to avoid expensive downstream chronic costs, and reducing delivery costs through technology. Specific tactics include automating admin tasks, using digital triage to utilize lower-cost healthcare professionals, and solving issues via digital consultations to reduce physical service costs.

The Investment Ask

Slide 10: Capital Raising Overview

The final slide in this set details the financial ask. Pure Medical is aiming to raise approximately £2.5M via a placement of 99,404 New B Shares. The offer price is set at £25.15 per share. The use of funds is clearly categorized: acquisition of medical machinery, development of clinical sites, additional headcount, and general working capital. A record date of November 1, 2021, is noted for the entitlement offer.

What Works in This Deck

Strong Public Sector Validation: The mention of a secured LOI with an NHS trust (Slide 2) is a significant credibility marker. For a private wellness company, showing a path into the public healthcare system suggests a level of clinical rigor that sets it apart from standard 'spas.' Clear Service Differentiation: Slide 6 effectively communicates the breadth of the offering. By listing ten distinct modalities, the company backs up its 'Blue Ocean' claim with specific, tangible services. Structured Patient Triage: The 'Care Pyramid' (Slide 7) demonstrates that the founders understand unit economics. It shows a plan to prevent the most expensive resources (doctors and physical clinics) from being overwhelmed by low-intensity queries, which is vital for scaling margins.

What Is Missing from This Deck

Team Background: In the provided slides, there is no mention of the founding team, medical directors, or advisors. In a medical-adjacent startup, the credentials of the clinical lead are paramount for investor trust. Current Financial Performance: While the deck mentions '60%+ margins' (Slide 2), it does not show historical revenue, current burn rate, or a detailed P&L. Investors need to see the starting point before they can buy into the 'expansion' story. Competitive Landscape: While the company claims a 'Blue Ocean,' it does not name specific competitors or explain why others haven't bundled these services yet. A comparison table against traditional clinics or high-end wellness clubs would provide necessary context. Regulatory and Compliance Status: Given the use of Ozone Therapy and Hyperbaric Oxygen, information regarding CQC (Care Quality Commission) registration or other UK medical certifications is a notable omission.

Founder Takeaways

Use a '5 Questions' Summary: Slide 2 is an excellent way to ground the investor immediately. By answering the most common questions upfront, you set the narrative for the rest of the deck. Visualize the 'Blue Ocean': If your competitive advantage is a 'one-stop-shop' model, use a grid or collage like Slide 6 to show the sheer volume of your offering. It is much more impactful than a bulleted list. Connect Tech to Margins: Don't just say you have an app; show how that app reduces your Cost of Goods Sold (COGS). Slide 9 does this well by linking digital triage directly to the use of 'lower cost healthcare professionals.' Be Specific with the Ask: Slide 10 is a model for clarity. It provides the share price, the number of shares, the total amount, and a clear breakdown of where that money goes. Avoid vague 'growth' buckets and specify 'medical machinery' or 'site development' where possible.

Frequently asked questions

What is the primary problem Pure Medical is addressing?: According to slide 2, Pure Medical is addressing the 31 million adults in the UK living with chronic pain. They aim to provide proactive wellness services that offer convenient, efficient, and intuitive experiences for injury recovery, athletic performance, and longevity, moving beyond the limitations of conventional healthcare disruption.
How does Pure Medical plan to integrate with the public health system?: Slide 2 notes that the company has secured a Letter of Intent (LOI) with the Milton Keynes NHS trust. This contract, intended to start in July 2022, provides a population catchment of 6.1 million public sector patients. They are also in ongoing negotiations with neighboring NHS trusts to expand this reach.
What specific medical treatments does the company offer?: Slide 6 lists ten distinct modalities: Hyperbaric oxygen therapy, Photobiomodulation therapy, Tailored medical plans, Cryotherapy, Far infrared sauna therapy, Ozone therapy, Cryolipolysis therapy, IV drip therapy, Physio+ therapy, and Compression therapy. Slides 4 and 5 provide deep dives into the science behind infrared sauna and ozone therapies.
What is the 'Care Pyramid' mentioned in the deck?: Slide 7 describes the Care Pyramid as a method to align resources with patient requirements. It scales from 'Digital Self-care' at the base (app-based monitoring) up through 'Personal Health Assistants' and 'Virtual Clinical Consultations' to 'In Person Consultation' and 'Tailored Healthcare' at the peak.
What are the terms of the current funding round?: As shown on slide 10, Pure Medical is raising approximately £2.5M. This is structured as a placement of 99,404 New B Shares priced at £25.15 per share. The funds are earmarked for the acquisition of medical machinery, development of clinical sites, and additional headcount.